Moreover, oral administration of withaferin A resulted in significant inhibition of the tumor growth in the prostate cancer model, due to a complete absence of metastatic lesions and downregulation of p-Akt expression, β-catenin, N-cadherin and epithelial to the mesenchymal transition (EMT) markers [24]. The gene discussed is AKT1; the disease is prostate carcinoma.